| Value | ₹9.55 Cr |
|---|---|
| Execution period | 6 months |
NSE filing, NSE: DCBBANK. Summary written from the filing by ALFA Finder's alert engine.
DCB Bank Ltd: key numbers
- Share price
- ₹189.55
- Market cap
- ₹6,109 Cr
- Revenue (annual)
- ₹7,404 Cr
- Net profit (annual)
- ₹731.6 Cr
- P/E (TTM)
- 7.3×Sector 19.5×
- Promoter holding
- 16.22%-0.01% QoQ
- FII holding
- 15.47%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from DCB Bank Ltd
All →DCB Bank Management Change
DCB Bank's senior executive Jayaram Vishwanath was relieved early and ceased as Senior Management Personnel on November 4, 2026. The exit was brought forward from November 10.
DCB Bank Employee Stock Options
DCB Bank allotted 81,100 equity shares to employees under its ESOP plan on October 30, 2026. Paid-up capital rose to 322,270,512 shares.
DCB Bank Annual General Meeting
DCB Bank seeks shareholder approval via postal ballot to re-appoint Thiyagarajan Kumar as Independent Director for three years. E-voting runs from 27 October to 25 November 2026.
DCB Bank Earnings Call Transcript: Key Takeaways
DCB Bank delivers record quarterly net profit, hitting long-term ROE targets early despite NIM compression.
- Call
- Guides 20% growth
DCB Bank Management Change
DCB Bank's board re-appointed Mr. Praveen Kutty as Managing Director & CEO for three years from April 29, 2027 to April 28, 2030, subject to RBI terms and shareholder approval. No monetary value is involved in this senior management decision.
- Execution
- April 29, 2027 to April 28, 2030
DCB Bank Investor Presentation: Key Takeaways
Q2FY27 PAT INR 236 cr (+28.54% YoY); advances INR 64,127 cr (+21.05%); deposits INR 76,839 cr (+18.62%); GNPA 2.29%, NNPA 0.73%, ROE 14.60%. Secured retail and MSME growth focus.
Other merger & restructuring announcements
All →Narayana Hrudayalaya Merger & Restructuring
Narayana Hrudayalaya's NCLT Bengaluru bench sanctioned the demerger of clinical services from its subsidiary NH Integrated Care. Order uploaded today; effectiveness awaits certified copy filings.
Abans Enterprises Merger & Restructuring
Abans Enterprises' board approved voluntary liquidation of wholly owned subsidiary AGJT, subject to shareholder approval. Completion is expected within one year.
- Execution
- Expected within one year, subject to approvals and statutory formalities
Max Estates Merger & Restructuring Worth ₹0.01 Cr
Max Estates will subscribe to 10,000 shares worth ₹1 lakh in a yet-to-be-incorporated real estate company. The entity awaits Ministry of Corporate Affairs approval.
- Value
- ₹0.01 Cr
Aurobindo Pharma Merger & Restructuring Worth ₹29 Cr
Aurobindo Pharma approved transferring 100% of Auro Pharma LLC, Russia, between wholly owned subsidiaries. Cash consideration is about INR 29 crore, subject to adjustments.
- Value
- ₹29.00 Cr
- Execution
- 60-90 days
Choice International Merger & Restructuring Worth ₹1.27 Cr
Choice International sold a unit or subsidiary to Arrowbridge Trade for Rs.1.275 Crore in cash. The buyer is unrelated and the deal is at arm's length.
- Value
- ₹1.27 Cr
Shringar House of Mangalsutra Merger & Restructuring Worth ₹5 Cr
Shringar House of Mangalsutra will incorporate a wholly owned jewellery subsidiary, subscribing Rs 5 Crore in cash. The subsidiary becomes a related party once formed.
- Value
- ₹5.00 Cr